229 related articles for article (PubMed ID: 25595007)
1. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
Gandjour A
Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
[TBL] [Abstract][Full Text] [Related]
2. Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.
Gandjour A; Gafni A; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):123-9. PubMed ID: 24354766
[TBL] [Abstract][Full Text] [Related]
3. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
4. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
5. Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.
Gandjour A
Appl Health Econ Health Policy; 2011 Mar; 9(2):65-71. PubMed ID: 21332250
[TBL] [Abstract][Full Text] [Related]
6. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
[TBL] [Abstract][Full Text] [Related]
8. Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
Ludwig S; Dintsios CM
Value Health; 2016 Dec; 19(8):1016-1025. PubMed ID: 27987628
[TBL] [Abstract][Full Text] [Related]
9. [Drug assessment: IQWiG, G-BA, and an international comparison].
Glaeske G
Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
[TBL] [Abstract][Full Text] [Related]
10. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
Mühlbacher AC; Sadler A
Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
[TBL] [Abstract][Full Text] [Related]
11. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
[TBL] [Abstract][Full Text] [Related]
12. The efficiency frontier approach to economic evaluation of health-care interventions.
Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P
Health Econ; 2010 Oct; 19(10):1117-27. PubMed ID: 20575151
[TBL] [Abstract][Full Text] [Related]
13. Added Therapeutic Value of Medicinal Products for French and German Health Technology Assessment Organizations: A Systematic Comparison.
Boucaud-Maitre D; Berdaï D; Salvo F
Value Health; 2021 Mar; 24(3):346-352. PubMed ID: 33641768
[TBL] [Abstract][Full Text] [Related]
14. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
15. Presenting Germany's drug pricing rule as a cost-per-QALY rule.
Gandjour A
Health Care Manag Sci; 2012 Jun; 15(2):103-7. PubMed ID: 22187356
[TBL] [Abstract][Full Text] [Related]
16. Institute for Quality and Efficiency in Health Care: Germany.
Nasser M; Sawicki P
Issue Brief (Commonw Fund); 2009 Jul; 57():1-12. PubMed ID: 19639711
[TBL] [Abstract][Full Text] [Related]
17. Drug Policy in the Czech Republic.
Skoupá J
Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
[TBL] [Abstract][Full Text] [Related]
18. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
Fischer KE; Stargardt T
Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
[TBL] [Abstract][Full Text] [Related]
19. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
[TBL] [Abstract][Full Text] [Related]
20. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
Blome C; Augustin M; Metin H; Lohrberg D
Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
